• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1991 年挪威心律失常先证者和 2782 名亲属的分子遗传学:国家实验室 17 年遗传检测结果。

Molecular genetics in 1991 arrhythmia probands and 2782 relatives in Norway: Results from 17 years of genetic testing in a national laboratory.

机构信息

Unit for Cardiac and Cardiovascular Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.

ProCardio Center for Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

出版信息

Clin Genet. 2024 Nov;106(5):585-602. doi: 10.1111/cge.14593. Epub 2024 Jul 29.

DOI:10.1111/cge.14593
PMID:39073097
Abstract

The aim of this study was to explore the prevalence of likely pathogenic or pathogenic variants and assess the diagnostic yield from genetic testing for cardiac arrhythmias in Norway since 2003. Data from 1991 probands and 2782 relatives were retrospectively collected from the laboratory information management system at Unit for Cardiac and Cardiovascular Genetics, Oslo University hospital. Of 1991 probands, 57.4% were females, age at genetic testing was 33.1 (±22.7) years, and 32.5% were under the age of 18. A likely pathogenic or pathogenic variant (including 14 novel) was detected in 15.4% in total. Of the 2782 relatives, 53.7% were females, age at genetic testing was 35.6 (±22.5) years, 27.3% were under the age of 18, and 45.3% carried the family variant. Probands and relatives combined, 1/3356 persons in the Norwegian population were heterozygous for an arrhythmia-causing variant. The founder variant p.Q530X (NM_000218.2: c.1588C>T) in KCNQ1 accounted for 34% of all variants in Norway. In conclusion, genetic testing provided a genetic basis of the arrhythmia in 15.4% of the probands. Familial cascade screening identified four times as many variant-positive relatives, allowing early detection and prompt stratification of arrhythmic risk of those variant carriers.

摘要

本研究旨在探讨自 2003 年以来挪威心脏心律失常基因检测中可能致病性或致病性变异的流行情况,并评估其诊断效果。从奥斯陆大学医院心脏和心血管遗传学系的实验室信息管理系统中回顾性收集了 1991 名先证者和 2782 名亲属的数据。1991 名先证者中,57.4%为女性,基因检测时的年龄为 33.1(±22.7)岁,32.5%的年龄在 18 岁以下。总共发现了 15.4%的可能致病性或致病性变异(包括 14 种新变异)。2782 名亲属中,53.7%为女性,基因检测时的年龄为 35.6(±22.5)岁,27.3%的年龄在 18 岁以下,45.3%携带家族变异。先证者和亲属合并后,挪威人群中每 3356 人就有 1 人携带心律失常致病变异的杂合子。KCNQ1 中的 p.Q530X(NM_000218.2:c.1588C>T)是导致挪威所有变异的 34%的主要变异。总之,基因检测为 15.4%的先证者提供了心律失常的遗传基础。家族级联筛查发现了四倍数量的变异阳性亲属,使这些变异携带者能够更早地发现和及时分层心律失常风险。

相似文献

1
Molecular genetics in 1991 arrhythmia probands and 2782 relatives in Norway: Results from 17 years of genetic testing in a national laboratory.1991 年挪威心律失常先证者和 2782 名亲属的分子遗传学:国家实验室 17 年遗传检测结果。
Clin Genet. 2024 Nov;106(5):585-602. doi: 10.1111/cge.14593. Epub 2024 Jul 29.
2
Catecholaminergic Polymorphic Ventricular Tachycardia儿茶酚胺能多形性室性心动过速
3
[Clinical and genetic characteristics of familial cases with Glucose transporter 1 deficiency syndrome].葡萄糖转运蛋白1缺乏综合征家族病例的临床及遗传特征
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2025 Apr 10;42(4):424-432. doi: 10.3760/cma.j.cn511374-20241009-00524.
4
ATP1A3 Variants, Variably Penetrant Short QT Intervals, and Lethal Ventricular Arrhythmias.ATP1A3基因变异、可变显性的短QT间期与致命性室性心律失常
JAMA Pediatr. 2025 May 1;179(5):529-539. doi: 10.1001/jamapediatrics.2024.6832.
5
Jervell and Lange-Nielsen Syndrome杰韦尔和朗格-尼尔森综合征
6
Familial Hypercholesterolemia家族性高胆固醇血症
7
Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing.个体接受遗传性癌症检测时同时进行 DNA 和 RNA 测序的诊断结果。
JAMA Oncol. 2024 Feb 1;10(2):212-219. doi: 10.1001/jamaoncol.2023.5586.
8
Hemophilia A甲型血友病
9
- and -Related Osteogenesis Imperfecta与……相关的成骨不全症 (你提供的原文不完整,推测这里可能是想表达“某种因素与成骨不全症相关”,但仅从现有的“- and -Related Osteogenesis Imperfecta”很难准确翻译出完整准确的内容,以上是基于可能情况的翻译 )
10
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.Elucigene FH20 和 LIPOchip 用于家族性高胆固醇血症的诊断:系统评价和经济评估。
Health Technol Assess. 2012;16(17):1-266. doi: 10.3310/hta16170.